Clinical Trial Update: Safety and Efficacy of RAP-103 to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in Subjects [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update describes safety and efficacy goals for RAP-103 in adults with moderate-to-severe psoriasis; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• RAP-103

Snippet

Sponsor: Clarent Biopharma, Inc. | Conditions: Psoriasis | Phase 2 | Status: NOT_YET_RECRUITING